Abstract
Meeting abstracts Adoptive T cell therapy (ACT) can promote dramatic regressions of established cancer, yet durable clinical responses are observed in only a subset of patients. ACT provides the opportunity to alter the immune suppressive host environment associated with cancer prior to
Highlights
Adoptive T cell therapy (ACT) can promote dramatic regressions of established cancer, yet durable clinical responses are observed in only a subset of patients
ACT provides the opportunity to alter the immune suppressive host environment associated with cancer prior to introduction of tumor-specific T cells
Here, we evaluated the utility of combined whole body irradiation and agonist anti-CD40 antibody to enhance ACT-mediated control of established autochthonous pancreatic tumors
Summary
Adoptive T cell therapy (ACT) can promote dramatic regressions of established cancer, yet durable clinical responses are observed in only a subset of patients. Whole body irradiation and agonist anti-CD40 synergize to promote adoptive T cell therapy of resistant murine pancreatic neuroendocrine tumors Lindsay Ward-Kavanagh, Timothy K Cooper, Aron Lukacher, Todd D Schell*
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
